OncoSignal
Indications / Non-small cell lung cancer · Breast cancer · Pancreatic cancer · Colorectal cancer · Acute myeloid leukemia · Chronic myeloid leukemia · Multiple myeloma · Glioblastoma · Glioma · Neuroblastoma · Medulloblastoma · Diffuse midline glioma (DIPG) · Ependymoma · Atypical teratoid rhabdoid tumour (AT/RT) · Childhood acute lymphoblastic leukemia · Ewing sarcoma · Osteosarcoma · Rhabdomyosarcoma

Neuroblastoma

High-risk and relapsed disease: MYCN amplification, ALK mutations and anti-GD2 therapy.

Live from ClinicalTrials.gov and PubMed, fetched 2026-11-11 15:18 UTC. Every row links to its source record.

Registry changes (new trials, status, phase, endpoint and readout-date changes, results) come from the OncoSignal store, last verified against ClinicalTrials.gov 2026-11-11 08:26 UTC.

Phase advances
0
since 2026-07-14
New Ph2+ trials
1
Results posted
1
Readouts due
4
primary completion reached
Trial papers
4
PubMed, last 60 days
  1. Paper
    Feasibility and Tolerability of Chemoimmunotherapy Given During Induction for Treatment of Patients With High-Risk Neuroblastoma: A Report From the Children's Oncology Group.

    Federico SM, Naranjo A, Zhang FF et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

    Publisher page
  2. Paper
  3. Results posted
    Results posted: NCT03033303

    A Study of the Effect of Hu3F8/GM-CSF Immunotherapy Plus Isotretinoin in Patients in First Remission of High-Risk Neuroblastoma

  4. Paper
  5. New trial
    New Ph1 trial: GD2CART-BEV (NCT07897968)

    Universität Münster. GD2IL18CART Combined With Bevacizumab for Relapsed and Refractory GD2-positive Solid Tumors

  6. Paper
    Efficacy and Safety of Alectinib in Pediatric and Adult Patients with ALK-Altered Advanced Solid Tumors: a phase II TACKLE Trial (NCCH1712/MK003).

    Okuma HS, Arakawa A, Hirakawa A et al. Clinical cancer research : an official journal of the American Association for Cancer Research.

    Publisher page
  7. Readout due
    Readout due: NCT05642455 reached primary completion

    USWM CT, LLC. SPEARHEAD-3 Pediatric Study

  8. Readout due
    Readout due: NCT02176967 reached primary completion

    Children's Oncology Group. Response and Biology-Based Risk Factor-Guided Therapy in Treating Younger Patients With Non-high Risk Neuroblastoma

  9. Readout due
    Readout due: NCT00911560 reached primary completion

    Memorial Sloan Kettering Cancer Center. Bivalent Vaccine With Escalating Doses of the Immunological Adjuvant OPT-821, in Combination With Oral β-glucan for High-Risk Neuroblastoma

  10. Readout due
    Readout due: NCT04724369 reached primary completion

    Innervate Radiopharmaceuticals LLC (Formerly: Illumina Radiopharmaceuticals LLC). Open-Label Study of 18F-mFBG for Imaging Neuroblastoma

A phase advance is an asset's first trial at a higher phase than any earlier trial of the same asset in this indication. Readout due means the registry's primary completion date has passed; it is not a disclosure.